U.S. Sclerotherapy Market Size & Outlook, 2020-2027
U.S. sclerotherapy market, 2016-2027 (US$M)
Related Markets
U.S. sclerotherapy market highlights
- The U.S. sclerotherapy market generated a revenue of USD 351.4 million in 2020 and is expected to reach USD 494.9 million by 2027.
- The U.S. market is expected to grow at a CAGR of 5% from 2021 to 2027.
- In terms of segment, detergents was the largest revenue generating agent in 2020.
- Detergents is the most lucrative agent segment registering the fastest growth during the forecast period.
Sclerotherapy market data book summary
| Market revenue in 2020 | USD 351.4 million |
| Market revenue in 2027 | USD 494.9 million |
| Growth rate | 5% (CAGR from 2020 to 2027) |
| Largest segment | Detergents |
| Fastest growing segment | Detergents |
| Historical data | 2016 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Detergents, Chemical Irritants, Osmotic Agents |
| Key market players worldwide | B2Gold Corp, LGM Pharma, Troikaa Pharmaceuticals, Mylan, Perrigo Co PLC, Merz Pharma, Medi-Globe |
Other key industry trends
- In terms of revenue, U.S. accounted for 38.8% of the global sclerotherapy market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In North America, U.S. sclerotherapy market is projected to lead the regional market in terms of revenue in 2027.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 494.9 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Sclerotherapy Market Scope
Sclerotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. sclerotherapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sclerotherapy market will help companies and investors design strategic landscapes.
Detergents was the largest segment with a revenue share of 42.03% in 2020. Horizon Databook has segmented the U.S. sclerotherapy market based on detergents, chemical irritants, osmotic agents covering the revenue growth of each sub-segment from 2016 to 2027.
Sclerotherapy market in the U.S. accounted for the largest share in the North America market. Rising geriatric population with venous diseases and higher adoption of less invasive procedures are some factors responsible for market growth in the U.S.
According to the U.S. Department of Health and Human Services Office, in 2019, Varicose and spider veins are highly prevalent in the country and around 50 to 55% of women and 40 to 45% of men suffer from some type of vein problem in the U.S.
According to Premier Health, around 30 million Americans suffer from venous disease, that includes varicose veins and chronic venous insufficiency (CVI), yet only 1.9 million seek treatment each year. Venous stasis ulcers affect approximately 500,000 people and the number of hospital admission for CVI is 92 per 100,000 admissions.
Reasons to subscribe to U.S. sclerotherapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. sclerotherapy market databook
-
Our clientele includes a mix of sclerotherapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. sclerotherapy market, including forecasts for subscribers. This country databook contains high-level insights into U.S. sclerotherapy market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. sclerotherapy market size, by agent, 2016-2027 (US$M)
U.S. Sclerotherapy Market Share, 2020 & 2027 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
